RNI Precision Trial Protocol: Optimization of Regional Node Irradiation for Sentinel Lymph Node-positive Breast Cancer Omitting Axillary Dissection Based on Clinical and Genomic Risk Assessment: A Prospective Clinical Trial
Technology in Cancer Research & Treatment · 2026-05 · 25
DOI: 10.1177/15330338261450066 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift Technology in Cancer Research & Treatment, online erschienen am 04.05.2026. Verfasst von Wei-Xiang Qi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Sentinel Lymph Node. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Shanghai Science and Technology Innovation Action Plan Medical Innovation Research Project, Shanghai Key Laboratory of Proton therapy, Clinical Research Special Project of Shanghai Municipal Health Commission Health Industry.
Abstract (Originalsprache)
Background
Sentinel lymph node biopsy (SLNB) has been the standard treatment procedure for clinically node-negative (cN0) breast cancer (BC). Three randomized trials (Z0011, AMAROS and SENOMAC) have shown that patients with low-burden sentinel lymph node metastasis can be safely omitted axillary lymph node dissection who receive adjuvant radiotherapy. However, these published studies have been insufficient to accurately assess the recurrence risk in this patient population, leading to variability in adjuvant radiotherapy volume across different studies.
Objective
This study evaluates whether an integrated axillary management strategy combining SLNB with individualized regional nodal irradiation (RNI) based on recurrence risk reduces 2-year lymphedema compared to ALND followed by comprehensive RNI. Materials and Methods This trial is a single institute, open-labeled, non-randomized cohort trial. Participants are stratified into two cohorts based on the extent of axillary surgery after enrollment. For SLNB cohort, patients are divided into three groups according to clinical and genomic risk assessment. Clinically high-risk patients are defined as having at least two factors (tumor size≥2cm, percent of positive SLNs>30%, LVI positive and SLN macro-metastases), who have a predicted risk of n-SLN involvement greater than 30%. Clinically high-risk n-SLN involvement patients are further detected by using RecurIndex test. For pathological node positive (pN+) after ALND cohort, patients are treated with WBI/chest wall irradiation combined with comprehensive RNI excluding the dissected axillary region; A total of 205 patients will be enrolled, with 68 patients in SLNB cohort and 137 patients in ALND cohort with a 1:2 ratio assignment. The RNI precision trial uses a clinical-genomic model to accurately stratify the recurrence risk and provides the individualized RNI volume for early-stage BC with low-burden sentinel lymph node metastasis, and we anticipate that our study will provide high-quality data to potentially support individualized RNI in this patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
- Shanghai Key Laboratory of Proton-therapy, Shanghai, China.
ORCID-Profile: Wei-Xiang Qi, Jiayi Chen
Förderung
- Shanghai Science and Technology Innovation Action Plan Medical Innovation Research Project
- Shanghai Key Laboratory of Proton therapy
- Clinical Research Special Project of Shanghai Municipal Health Commission Health Industry
Zitieren
APA
Qi, W. X., Cao, L., Zheng, S., Li, S., Xu, F., Xu, C., Cai, R., Cai, G., & Chen, J. (2026). RNI Precision Trial Protocol: Optimization of Regional Node Irradiation for Sentinel Lymph Node-positive Breast Cancer Omitting Axillary Dissection Based on Clinical and Genomic Risk Assessment: A Prospective Clinical Trial. Technology in Cancer Research & Treatment, 25. https://doi.org/10.1177/15330338261450066
Vancouver
Qi WX, Cao L, Zheng S, Li S, Xu F, Xu C, et al. RNI Precision Trial Protocol: Optimization of Regional Node Irradiation for Sentinel Lymph Node-positive Breast Cancer Omitting Axillary Dissection Based on Clinical and Genomic Risk Assessment: A Prospective Clinical Trial. Technology in Cancer Research & Treatment. 2026;25. doi:10.1177/15330338261450066
BibTeX
@article{Qi2026,
author = {Qi, Wei-Xiang and Cao, Lu and Zheng, Siyue and Li, Shuyan and Xu, Feifei and Xu, Cheng and Cai, Rong and Cai, Gang and Chen, Jiayi},
title = {RNI Precision Trial Protocol: Optimization of Regional Node Irradiation for Sentinel Lymph Node-positive Breast Cancer Omitting Axillary Dissection Based on Clinical and Genomic Risk Assessment: A Prospective Clinical Trial},
journal = {Technology in Cancer Research & Treatment},
year = {2026},
volume = {25},
doi = {10.1177/15330338261450066}
}
EUVIMED